Effectiveness of Medical Taping Concept in Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Nausea and vomiting are two of the side effects associated with the most common antineoplastic chemotherapy treatments. The Medical Taping Concept (MTC) is an economical technique, easy to apply. This is a technique that may help reduce nausea and vomiting after application of chemotherapy in cancer patient.

Detailed Description
-----------------
Nausea and vomiting are two of the side effects associated with the most common antineoplastic chemotherapy treatments. There are some studies that support the use of physical measures such as TENS or acupuncture to lessen these effects. The Medical Taping Concept (MTC) is an economical technique, easy to apply and few side effects. In some manuals on this technique the possibility that it may act to reduce nausea and vomiting described. Sim But after a comprehensive literature search have not found jobs to support these assumptions. With this work, the research team will attempt to obtain evidence on the effects of its application in the areas of influence of the dermatome T7 and T8. For this, two adhesive tapes of this type of bandage is placed on the front and back on a group of patients after receiving chemotherapy session and compared with a control group that will apply this technique outside the dermatome indicated . Both groups will receive antiemetics according to the service routine. If the hypothesis were positive it could extend the application of this simple technique to cancer patients from other centers in order to help reduce nausea and vomiting.

Official Title
-----------------
Effectiveness of Medical Taping Concept Applied in the T7-T8 Dermatome in Nausea and Vomiting After Chemotherapy in Cancer Patients

Conditions
-----------------
Cancer-related Problem/Condition

Intervention / Treatment
-----------------
* Device: Cure Tape™ covering T 7 and T 8 dermatomes
* Device: Cure Tape™ away from dermatomes T 7 and T 8


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neoadjuvant and adjuvant breast cancer To have been diagnosed with a severe comorbid disorder To have received at least the first cycle of emetogenic chemotherapy Exclusion Criteria: Not suffer nausea or vomiting episodes in the previous cycle of chemotherapy, To Shower inability to report nausea and / or vomiting.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention group<br>One piece of a special hypoallergenic adhesive tape, called Cure Tape®, they will have a size of 12-20 cm and will be attached in the front and back torso area on the T7- T8 dermatomes. | Device: Cure Tape™ covering T 7 and T 8 dermatomes<br>* The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.<br>* Other names: Kinesio Taping;|
| Placebo Comparator: Placebo group<br>Two piece of a special hypoallergenic adhesive tape, called Cure Tape®, have a size of 2.5 cm x 2 cm and they will have to be placed near the greater trochanter area. | Device: Cure Tape™ away from dermatomes T 7 and T 8<br>* The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.<br>* Other names: Kinesio Taping;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between Number of times you have vomited during the first 24 hours after the first chemotherapy session and after the second chemotherapy session | 1, 2, 3, 4, 5, ......... | 24 hours after the first chemotherapy session and 24 hours after the second chemotherapy session | 
| Difference between nausea after the first chemotherapy session and after the second chemotherapy session | Nausea (Yes / No) | 24 hours after the first chemotherapy session and 24 hours after the second chemotherapy session | 
| Difference between Intensity of nausea in the experience of the participant after the first chemotherapy session and after the second chemotherapy sessionintervention and pre-intervention | numerical scale from 0 to 10 (0 = No / 10 = maximum) | 24 hours after the first chemotherapy session and 24 hours after the second chemotherapy session | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between Quality of life post-intervention and pre-intervention | EQ-5D™ is a standardised instrument for use as a measure of health outcome | 24 hours after chemotherapy and 4 days after chemotherapy |